MX2020004148A - Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf). - Google Patents
Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf).Info
- Publication number
- MX2020004148A MX2020004148A MX2020004148A MX2020004148A MX2020004148A MX 2020004148 A MX2020004148 A MX 2020004148A MX 2020004148 A MX2020004148 A MX 2020004148A MX 2020004148 A MX2020004148 A MX 2020004148A MX 2020004148 A MX2020004148 A MX 2020004148A
- Authority
- MX
- Mexico
- Prior art keywords
- raf kinase
- crystalline salts
- kinase inhibitor
- inhibitor
- crystalline
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- 229940102297 B-raf kinase inhibitor Drugs 0.000 title 1
- 239000002774 b raf kinase inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- AEJACXAFHXBVHF-UHFFFAOYSA-N n-[3-[5-[(1-ethylpiperidin-4-yl)-methylamino]-3-pyrimidin-5-ylpyrrolo[3,2-b]pyridin-1-yl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(N2C3=CC=C(N=C3C(C=3C=NC=NC=3)=C2)N(C)C2CCN(CC)CC2)=C1F AEJACXAFHXBVHF-UHFFFAOYSA-N 0.000 abstract 1
- 102000009929 raf Kinases Human genes 0.000 abstract 1
- 108010077182 raf Kinases Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577313P | 2017-10-26 | 2017-10-26 | |
| PCT/US2018/057792 WO2019084459A1 (en) | 2017-10-26 | 2018-10-26 | CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004148A true MX2020004148A (es) | 2022-09-09 |
Family
ID=64277870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004148A MX2020004148A (es) | 2017-10-26 | 2018-10-26 | Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf). |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11306086B2 (https=) |
| EP (2) | EP4245758A3 (https=) |
| JP (2) | JP7230041B2 (https=) |
| KR (1) | KR102820822B1 (https=) |
| CN (2) | CN111818924B (https=) |
| AU (2) | AU2018355528B2 (https=) |
| BR (1) | BR112020008248A2 (https=) |
| CA (1) | CA3080324A1 (https=) |
| ES (1) | ES2947411T3 (https=) |
| IL (1) | IL274027B2 (https=) |
| MX (1) | MX2020004148A (https=) |
| MY (1) | MY203853A (https=) |
| PH (1) | PH12020550485A1 (https=) |
| SG (1) | SG11202003635TA (https=) |
| WO (1) | WO2019084459A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202003635TA (en) | 2017-10-26 | 2020-05-28 | Xynomic Pharmaceuticals Inc | Crystalline salts of a b-raf kinase inhibitor |
| JP2022069426A (ja) * | 2020-10-23 | 2022-05-11 | マイラン ラボラトリーズ リミテッド | テネリグリプチン２．５臭化水素酸塩のアモルファスを調製する方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| CA2546192C (en) * | 2003-11-17 | 2010-04-06 | Pfizer Products Inc. | Pyrrolopyrimidine compounds useful in treatment of cancer |
| GB0423554D0 (en) * | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| UA95244C2 (ru) | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| WO2007123892A2 (en) * | 2006-04-17 | 2007-11-01 | Arqule Inc. | Raf inhibitors and their uses |
| EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| US20110183975A1 (en) | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| MY160064A (en) * | 2009-09-28 | 2017-02-15 | Hoffmann La Roche | Benzoxazepin pi3k inhibitor compounds and methods of use |
| US8889684B2 (en) * | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| JP6263469B2 (ja) | 2011-07-15 | 2018-01-17 | ノバルティス アーゲー | アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法 |
| PL2945628T3 (pl) * | 2013-01-15 | 2020-09-21 | Aragon Pharmaceuticals, Inc. | Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| CN116271056A (zh) | 2015-04-16 | 2023-06-23 | 日东电工株式会社 | 针对具有braf基因突变的细胞的细胞死亡诱导试剂、该细胞的增殖抑制试剂及用于治疗由该细胞的增殖异常导致的疾病的医药组合物 |
| CN105801584B (zh) * | 2016-03-16 | 2019-03-05 | 中国药科大学 | 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途 |
| SG11202003635TA (en) | 2017-10-26 | 2020-05-28 | Xynomic Pharmaceuticals Inc | Crystalline salts of a b-raf kinase inhibitor |
-
2018
- 2018-10-26 SG SG11202003635TA patent/SG11202003635TA/en unknown
- 2018-10-26 CN CN201880081003.9A patent/CN111818924B/zh active Active
- 2018-10-26 WO PCT/US2018/057792 patent/WO2019084459A1/en not_active Ceased
- 2018-10-26 MY MYPI2020001994A patent/MY203853A/en unknown
- 2018-10-26 JP JP2020543248A patent/JP7230041B2/ja active Active
- 2018-10-26 CN CN202310913355.9A patent/CN116942672B/zh active Active
- 2018-10-26 US US16/759,187 patent/US11306086B2/en active Active
- 2018-10-26 CA CA3080324A patent/CA3080324A1/en active Pending
- 2018-10-26 KR KR1020207014962A patent/KR102820822B1/ko active Active
- 2018-10-26 AU AU2018355528A patent/AU2018355528B2/en active Active
- 2018-10-26 IL IL274027A patent/IL274027B2/en unknown
- 2018-10-26 EP EP23167989.5A patent/EP4245758A3/en not_active Withdrawn
- 2018-10-26 EP EP18801183.7A patent/EP3700530B1/en active Active
- 2018-10-26 BR BR112020008248-1A patent/BR112020008248A2/pt not_active IP Right Cessation
- 2018-10-26 ES ES18801183T patent/ES2947411T3/es active Active
- 2018-10-26 MX MX2020004148A patent/MX2020004148A/es unknown
-
2020
- 2020-04-24 PH PH12020550485A patent/PH12020550485A1/en unknown
-
2022
- 2022-02-17 AU AU2022201044A patent/AU2022201044B2/en active Active
- 2022-03-11 US US17/692,695 patent/US11753409B2/en active Active
-
2023
- 2023-02-15 JP JP2023021816A patent/JP2023062074A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004148A (es) | Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf). | |
| CY1123796T1 (el) | Στερεες μορφες μιας ενωσης που τροποποιει κινασες | |
| SA520411638B1 (ar) | Tam أملاح لمشتقات بيرولو ترايازين مفيدة كمثبطات لـ | |
| JOP20190077A1 (ar) | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret | |
| JOP20190076B1 (ar) | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret | |
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| BR112015021995A2 (pt) | combinações de inibidores de tirosina quinase de bruton e inibidores de cyp3a4 | |
| EA201691484A1 (ru) | Соли и твердая форма ингибитора btk | |
| EA201591255A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK) | |
| AR100818A1 (es) | N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
| CL2016001895A1 (es) | Compuestos | |
| DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| MX384833B (es) | Inhibidores de tirosina quinasa de bruton | |
| EA201890820A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1 | |
| EA202091475A1 (ru) | ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА | |
| EA201992147A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| EA201891768A1 (ru) | Кристаллическая форма a агониста tlr7, ее способ получения и использование | |
| MX2017005255A (es) | Derivados de carbazol. | |
| PH12019501022A1 (en) | Pyrazolopyrimidine compounds and methods of use thereof | |
| MX374552B (es) | Derivados de 2-fenil-3h-imidazo[4,5-b]piridina útiles como inhibidores de actividad de receptor huérfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamífero. | |
| MX2017013248A (es) | Compuesto del inhibidor fgfr4 cristalino y usos del mismo. | |
| CL2021000580A1 (es) | Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares. |